drug-discovery

Analyze drug-likeness and ADMET properties by applying Lipinski, Veber, CNS penetration, metabolism, and toxicity heuristics to assess compound developability. This process evaluates molecular properties retrieved from public chemistry databases to identify potential safety risks.

Compound profiling and target search work by querying free-public APIs like ChEMBL and PubChem to retrieve bioactive compound data and extract structured molecular properties. This allows researchers to inspect molecule properties and gather activity data for pharmaceutical targets.

Yes, you can use this for lead optimization workflows and optional script-driven batch processing. Medicinal chemists can screen a shortlist of leads, compare their molecular properties, and identify optimization opportunities before the next synthesis cycle.

The best way to look up drug interactions and disease associations is querying integrated pharmacology data sources like OpenTargets. This retrieves adverse event signals and gene-disease associations, providing safer decision-making context for drug discovery.

Yes, this drug discovery tool supports free-public API querying and rule-based assessment without external dependencies. It extracts structured property data from public databases to evaluate compounds, targets, and safety signals automatically.

You need to check Veber rules and CNS penetration during drug discovery to evaluate compound developability and predict absorption or distribution. Applying these pharmacology heuristics helps identify optimization opportunities and safety risks early.